CD8A and neoplasm: Taken together, despite the fact that tumor control was primarily CD8+ T cell dependent, the additional therapeutic benefit afforded by concomitant MS-275 delivery may not have relied on the additional recruitment of target antigen–specific CD8+ T cells or other antitumor lymphocyte populations.